doi: 10.1161/CIRCULATIONAHA.106.655753
(Circulation. 2007;115:3224-3234.)
© 2007 American Heart Association, Inc.
Interventional Cardiac Electrophysiology |
Interventional Electrophysiology in Patients With Congenital Heart Disease
From the Electrophysiology Division, Department of Cardiology, Children’s Hospital Boston, and Department of Pediatrics, Harvard Medical School, Boston, Mass.
Correspondence to Edward P. Walsh, MD, Cardiac Electrophysiology, Children’s Hospital Boston, 300 Longwood Ave, Boston, MA 02115. E-mail epwalsh{at}cardio.tch.harvard.edu
Key Words: arrhythmia • atrial flutter • catheter ablation • heart defects, congenital • pacemakers • Wolff-Parkinson-White syndrome
 |
Introduction |
|---|
 Top Introduction Mechanism and Incidence of...Catheter Ablation in CHDSurgery for Arrhythmias in...Pacemaker and Implantable...ConclusionsReferences |
|---|
"The treatment of congenital heart disease is unsatisfactory. As a rule, nothing can be done to improve patients symptomatically; in some instances digitalis may be of help."— —L. Emmett Holt, MD, 1933
On August 26, 1938, Dr Robert Gross performed the first successful surgery for a congenital heart defect by closing a patent ductus arteriosus in a 7-year-old girl. The event marked the beginning of an interventional approach to congenital heart disease (CHD) that forever banished the sort of pessimism expressed by Dr Holt in his classic pediatric textbook only 5 years earlier.1 Subsequent diagnostic and operative innovations ultimately led to surgical solutions for nearly all anatomic heart defects, allowing the vast majority of infants born with CHD in the modern era to survive into adulthood. However, improved hemodynamic longevity has exposed alternate sources of morbidity and mortality for this population, central among which are cardiac rhythm disorders. In some instances, arrhythmias are intrinsic to the CHD lesion itself, but in most cases, they arise as an unintended consequence of prior corrective surgery whenever patches and suture lines function in conjunction with hypertrophy and fibrosis to create the substrate for reentrant tachycardias. It is fortunate that improved understanding of rhythm abnormalities in CHD has coincided with the emergence of interventional electrophysiological techniques. Catheter ablation, arrhythmia surgery, pacemakers, and implantable defibrillators have now become indispensable treatment options for this group. It is the purpose of this article to review the application of these tools to CHD with an emphasis on unique technical challenges.
|
Mechanism and Incidence of Arrhythmias in CHD |
|---|
|
TopIntroductionMechanism and Incidence of...Catheter Ablation in CHDSurgery for Arrhythmias in...Pacemaker and Implantable...ConclusionsReferences |
|---|
Congenital heart defects occur in roughly 0.8% of live births, and in 30% to 50% of cases, the malformations are severe enough to warrant
1 surgical procedures during early childhood.2 Arrhythmia mechanisms vary according to the underlying anatomic defect and method of surgical repair. The electric pathophysiology involves a complex interplay between gross cardiac anatomy, chamber enlargement from abnormal pressure and volume loads, cellular injury from hypoxia and cardiopulmonary bypass, fibrosis at sites of suture lines and patches, and direct trauma to the specialized conduction tissues. A more likely environment for arrhythmia generation can hardly be imagined. The principal forms of CHD are listed in order of prevalence in the Table, along with an estimate of the relative risk for specific arrhythmias in each condition.
|
Atrial Tachycardias
The most common arrhythmia mechanism in CHD patients involves a macroreentrant circuit within abnormal atrial muscle. This disorder is conventionally referred to as intra-atrial reentrant tachycardia (IART) to distinguish it from macroreentrant atrial flutter, which occurs in patients with normal anatomy. The P-wave contour during IART often differs from the familiar sawtooth appearance of flutter because the reentrant path does not necessarily propagate around the tricuspid valve ring but instead may rotate around patches, atriotomy incisions, and other atypical conduction obstacles.3–5 Furthermore, IART tends to be slower than flutter, with atrial rates typically in the range of 150 to 250 per minute. This can result in episodes of 1:1 conduction with resultant hypotension or even circulatory collapse in patients with limited myocardial reserve.6 Thromboembolic complications can also arise if episodes are protracted.7
Although IART can develop in the setting of nearly any CHD lesion,8 it is especially problematic after the Fontan operation for single ventricle and the Mustard or Senning operation for transposition of the great arteries (D-TGA). Up to 50% of single-ventricle patients who have undergone older variations of the Fontan procedure will develop IART within a decade of surgery,9,10 as will 
30% of patients after Mustard or Senning repair.11 Apart from anatomic lesion and type of surgery, other risk factors for IART include concomitant sinus node dysfunction (tachy-brady syndrome) and older age at the time of heart surgery.6,9
Acute termination of IART episodes can be accomplished reliably with standard maneuvers such as electric cardioversion, but the far greater challenge is prevention of recurrence.6 Experience with antiarrhythmic drug therapy in this condition has been discouraging even when class Ic and III agents are used12; hence, the contemporary approach to IART treatment has shifted largely to interventional procedures.
Although far less common than IART, atrial fibrillation can develop in a subset of CHD patients who have conditions that result in marked left atrial dilation such as unrepaired atrial septal defects, left-sided valve disease, and dysfunction of their systemic ventricle.13
Accessory Atrioventricular Pathways
The incidence of accessory pathways in CHD is not appreciably higher than in the general population, with the 2 notable exceptions of Ebstein’s anomaly of the tricuspid valve and "congenitally corrected" transposition of the great arteries (L-TGA) in which an Ebstein’s-like malformation of the systemic atrioventricular (AV) valve often exists.14 The high incidence of accessory pathways in these 2 conditions suggests a probable developmental link between the valve deformity and the abnormal conduction tissue. As many as 20% of patients with Ebstein’s will have Wolff-Parkinson-White syndrome, and multiple accessory pathways will be found at mapping studies in nearly half of these cases.15 The situation can be aggravated further by atrial enlargement, leading to IART or atrial fibrillation with the potential for rapid anterograde conduction over the abnormal pathways.16,17 Catheter ablation has become the preferred treatment of this condition, although, as discussed later in this review, procedures tend to be more difficult than ablation in a normal heart.
Ventricular Tachycardia and Sudden Cardiac Death
Sudden arrhythmic death occurs with disturbing frequency in certain forms of CHD as patients reach adolescence and adulthood. Rapidly conducted IART or bradycardia may be the culprits in rare cases, but most of these events appear to involve ventricular tachycardia (VT). Patients at highest risk for VT are those who have undergone a ventriculotomy or patching of a ventricular septal defect (eg, tetralogy of Fallot repair) in which a macroreentrant circuit develops near the region of surgical scar.18–20 Alternatively, VT can develop in the setting of a more generalized myopathic process without discrete ventricular scars (eg, chronic aortic valve disease or a failing right ventricle after the Mustard and Senning procedures) if long-standing hemodynamic stress causes advanced degrees of ventricular hypertrophy or global dysfunction.21–23
Most published experience with VT in CHD involves tetralogy of Fallot. The prevalence of VT in this condition has been measured in the range of 3% to 14% in several large series, with a risk for sudden death estimated at 2% per decade of follow-up.24–28 Studies seeking risk factors for VT have identified clinical variables with modest predictive value, including: (1) older age at surgery, (2) older age at follow-up, (3) history of prior palliative shunts, (4) high-grade ventricular ectopy on Holter monitoring, (5) inducible VT at electrophysiological study, (6) poor right-heart hemodynamics, and (7) prolonged QRS duration on standard ECG.29–34 This list provides good sensitivity but poor specificity for identifying the tetralogy patient at risk.
Similar to the interventional approach that has been adopted for sudden death prevention in ischemic heart disease and cardiomyopathy, treatment for CHD patients with documented or suspected VT has moved away from drug therapy to focus predominantly on implantable defibrillators and ablation procedures.35 It should perhaps be emphasized that many CHD patients will also require hemodynamic interventions in the course of VT treatment such as valve replacement, relief of conduit stenosis, or closure of residual septal defects.36 Optimal management obviously requires attention to the broad cardiovascular picture, not just the arrhythmia in isolation.
Sinus Node Dysfunction and AV Block
Direct injury to the sinus node can occur with surgical incisions or suturing in the high right atrium. The Fontan, Glenn, Mustard, and Senning operations are notorious in this regard.9–11,37 More than 50% of survivors from the Mustard operation, for instance, have lost reliable sinus rhythm by adulthood. The resultant chronotropic incompetence limits exercise capacity, aggravates AV valve regurgitation, and contributes to a higher incidence of IART. Pacemaker therapy becomes necessary for many of these patients, although distorted anatomy can make standard transvenous implant challenging.
Disorders of AV conduction can arise in CHD patients from either developmental abnormalities of the conduction tissues or direct trauma. In 2 very specific malformations, AV canal defect and L-TGA, the AV node is anatomically displaced outside the normal triangle of Koch,38–41 and functional conduction properties are depressed. About 5% of L-TGA patients will exhibit complete AV block at birth, and a number of others have a progressive decline in conduction over the first 2 decades of life, so 20% of this group will require pacing for complete block by adulthood.42,43 Furthermore, the conduction tissues are very susceptible to injury during catheter and surgical procedures in canal defects and L-TGA.44 Even in conditions in which the conduction tissues are developmentally normal and properly situated in Koch’s triangle, a small number of patients will suffer traumatic AV block during closure of standard ventricular septal defects, surgery for left-heart outflow obstruction, or AV valve replacement.45 Surgically induced heart block that is not expected to resolve or persists >7 days after surgery is viewed as a class I indication for permanent pacing.
|
Catheter Ablation in CHD |
|---|
|
TopIntroductionMechanism and Incidence of...Catheter Ablation in CHDSurgery for Arrhythmias in...Pacemaker and Implantable...ConclusionsReferences |
|---|
Catheter ablation has been applied successfully to most forms of tachycardia in CHD patients. The major challenge during these cases is distorted anatomy that invalidates customary fluoroscopic landmarks and complicates catheter manipulation. Details of the underlying structural disease and all surgery need to be understood in advance of the intervention by reviewing past catheterization and operative data, along with prior noninvasive imaging studies. Angiography or echocardiography can be used to further clarify chamber orientation and to locate the true level of the AV groove at the time of the procedure (Figure 1A through 1C). To minimize the likelihood of inadvertent damage to the normal conduction tissues with ablation, it is also essential to recognize the atypical conduction patterns in certain forms of CHD and to carefully locate a high-quality His potential.46
|
Most laboratories performing ablation in CHD patients are now equipped with systems for 3-dimensional mapping, which has improved success rates for complex targets such as IART and VT.47 In addition, new software permitting 3-dimensional maps to be merged with magnetic resonance or computerized tomography images adds a level of sophistication to anatomic definition during ablation in CHD (Figure 2). Because thickened atrial and ventricular chamber walls are common in this population, irrigated ablation catheters and large-tip catheters with high-output radiofrequency (RF) generators are often required for effective lesion creation.48
|
yellow
Catheter Ablation for IART in CHD
Atrial mapping experience with IART in CHD has uncovered clear patterns for circuit propagation that depend on the underlying anatomy and type of repair.49 As a general rule, IART is restricted to right atrial tissue, and if a tricuspid valve is present, the isthmus between the valve ring and the inferior vena cava is a common component of such circuits.50 Patients with 4 cardiac chambers in normal orientation (eg, atrial septal defect, tetralogy of Fallot) can therefore be expected to have relatively straightforward circuits that resemble common atrial flutter, traveling around the tricuspid valve ring through the cavotricuspid isthmus (Figure 3A). An additional circuit around an atriotomy scar on the lateral right atrium4 also can be present in some of these cases (Figure 3B).
|
Circuits become more complicated whenever right atrial anatomy is distorted by abnormalities of atrial situs, atresia of an atrioventricular valve and ventricle, and surgical septation that sequesters portions of the right atrium into the pulmonary venous atrium. For example, when caval return is baffled toward the mitral valve as in D-TGA patients who have undergone the Mustard or Senning operation, the cavotricuspid isthmus is still likely to participate in reentry, but most of the critical isthmus tissue is located on the left side of the circulation. The catheter has to be delivered by a retrograde arterial approach or transbaffle puncture to reach this site for ablation.51–54
By far the most complex cases involve patients with a single ventricle after one of the many modifications of the Fontan operation in which the right AV valve and cavotricuspid isthmus are usually absent and the atrial chamber is massively enlarged. Multiple circuits can be present in this setting, with reentry around lateral wall atrial scars (Figure 4), atrial septal patches, or the region of anastomosis between the atrium and the pulmonary artery.3,54,55
|
The basic technique for IART mapping involves collection of electrograms from one or both atria during sustained tachycardia, incorporating enough data points to establish the activation sequence over the entirety of the IART cycle length. This pattern can then be viewed in the context of surgical scars and natural conduction barriers to arrive at a rational model for macroreentry. Entrainment pacing with analysis of postpacing intervals can be used to decipher complex circuits when uncertainty exists.56
Ablation can be attempted once the route for propagation has been established with reasonable certainty, but even when tachycardia location is firm, the task of creating an effective line of conduction block in CHD patients with thickened and dilated atrial chambers is demanding. Quite often, the target area is wider than the average lesion dimension of a single RF application, so multiple contiguous lesions have to be placed to establish permanent block in the target area. This leaves open the possibility of small gaps between application sites or variable depth for RF penetration that fails to produce transmural injury. This limitation has been addressed reasonably well with the widespread adoption of large-tip and irrigated designs for RF catheters.48
The combination of improved mapping with 3-dimensional technology and enhanced lesion creation has improved the acute success rates for IART ablation from 60% more than a decade ago to nearly 90% in the present era.47 Unfortunately, recurrence of the original IART or some new circuit remains disappointingly common. About 20% of patients with 4-chamber hearts will experience at least 1 episode of IART within 3 years of ablation, but the recurrence risk is particularly high (nearly 40%) in the Fontan population, who tend to have the largest number of IART circuits and the thickest atrial tissue.57 Although still far from perfect, outcomes are superior to the degree of control obtained with antiarrhythmic drugs alone, in which nearly 70% of patients have breakthrough IART within 2 years of starting a medication.12 Furthermore, even if IART episodes are not eliminated entirely by ablation, the procedure can provide effective palliation by reducing the frequency of episodes and eliminating the need for long-term drug therapy.47
Catheter Ablation of Accessory Pathways in CHD
Most published experience with accessory pathway ablation in CHD has involved Ebstein’s anomaly, in which the abnormal pathways are located almost exclusively in the region of the abnormal tricuspid valve.58,59 It is important to distinguish between the mobile edge of the valve leaflets in Ebstein’s (typically displaced down into the body of the right ventricle) and the true AV groove (marked by the course of the right coronary artery). The latter is the proper level for ablation but can be difficult to identify in this disease by standard fluoroscopy and electrogram characteristics alone (Figure 5). A right coronary angiogram will usually simplify this task and establish a useful roadmap for catheter navigation. Thin-caliber electrode catheters also have been used in some exceptional cases to map the right AV groove from within the lumen of the right coronary artery.60
|
Dilated right heart structures, fractionated electrograms, and a high incidence of multiple pathways all increase the challenge of accessory pathway ablation in Ebstein’s anomaly. Additionally, limits exist to how aggressive lesion creation can be because instances of coronary artery injury have been reported with standard RF applications along the exceptionally thin right AV groove in this condition.61 Thus, procedural outcomes fall short of what could be expected for a structurally normal heart, with acute success in 85% of Ebstein’s cases and pathway recurrence in as many as 25%.
Accessory pathways can be seen sporadically in malformations other than Ebstein’s. The list of associated structural anomalies ranges from simple atrial septal defect to complex heterotaxy with single ventricle. The decision to ablate often is motivated by an impending cardiac operation involving patching or vascular redirection that might block future catheter access to the pathway region. Successful procedures once again demand clear anatomic definition, accurate localization of the AV groove, and knowledge of AV node location.46,59,62 Reported outcomes for non-Ebstein’s CHD patients leave room for improvement, with acute success in only 80% and recurrence in 15%. Many of the ablation failures involve small patients with complex anatomy and accessory pathways in close proximity to the AV node in whom RF applications pose a risk of heart block. The recent availability of cryocatheter ablation with an enhanced safety margin near the AV node should improve results for such cases.63
Catheter Ablation for VT in CHD
Published experience with catheter ablation for VT in CHD remains limited. Most data exist in the form of single case reports, confirming that monomorphic VT can be induced with programmed stimulation to replicate clinical tachycardia, that macroreentrant circuits can be mapped accurately in conditions like tetralogy, and that VT can be extinguished with RF ablation.64–73 Varied mapping strategies have been described, including activation sequence analysis, entrainment maneuvers, pace mapping, and 3-dimensional registration (Figure 6). Although these data are interesting and important, a case report format cannot account for ablation failures, nor is follow-up sufficiently uniform to examine the issue of VT recurrence. Only 2 small series involving a combined total of 30 subjects have been assembled to address these questions.74,75 Among these subjects, the underlying lesion was tetralogy of Fallot in 17, ventricular septal defect in 8, and miscellaneous CHD in the remaining 5. Acute RF ablation success was achieved during 25 of the 28 procedures when mapping was possible (89%), although later VT recurrence was documented in 5 cases (20%). Some degree of recurrence is not surprising, considering the difficulty with RF lesion creation in the often thick-walled chamber like the right ventricle of tetralogy. The obvious question thus becomes whether catheter ablation can ever function as exclusive therapy for CHD patients when the consequences of VT recurrence could be catastrophic. Carefully selected CHD patients with single circuits of well-tolerated VT and otherwise good hemodynamics might be viewed as suitable candidates for primary catheter therapy, but if VT is rapid or causes serious symptoms, RF ablation usually is relegated to a secondary role as a way of reducing the shock burden in patients with frequent tachycardia episodes who already have a defibrillator in place.
|
|
Surgery for Arrhythmias in CHD |
|---|
|
TopIntroductionMechanism and Incidence of...Catheter Ablation in CHDSurgery for Arrhythmias in...Pacemaker and Implantable...ConclusionsReferences |
|---|
Cardiac surgery can serve either a preventive or a therapeutic role in arrhythmia management for CHD patients. Within the prevention category is a long list of modifications in technique and timing of corrective operations that have significantly reduced the incidence of late arrhythmias. A good example involves D-TGA, which is now managed with a direct arterial switch operation in the newborn period, rendering the complex atrial baffles of the Mustard and Senning operations nearly obsolete. This new approach not only offers hemodynamic advantages by retaining the left ventricle in the systemic circulation but also has effectively abolished the late complications of IART and sinus node dysfunction in this condition.76 Similarly, modern variations in the Fontan operation for single ventricle (such as the "lateral tunnel" and "extracardiac conduit") now channel systemic venous return directly to the pulmonary arteries via a cavopulmonary connection, thereby averting the massive atrial enlargement seen with the old-style anastomosis between the right atrium and pulmonary circulation. The incidence of postoperative IART for single-ventricle patients has decreased substantially as a consequence.77,78 The risk of ventricular arrhythmias also has been reduced in conditions such as tetralogy of Fallot by performing surgery at younger ages with smaller right ventricular incisions and more attention to pulmonary valve competence.79,80
Therapeutic arrhythmia surgery is used predominantly in the older generation of CHD patients who were repaired with outmoded techniques. These operations usually have the combined goals of tachycardia elimination and improvement of hemodynamics.
Fontan Conversion and Atrial Maze
Management of IART in the older Fontan population repaired with atriopulmonary connections requires a large arsenal of treatment options. Catheter ablation or pacemaker implantation can be effective in many cases, but if these measures fail or are otherwise deemed unsatisfactory, surgery can be considered that involves conversion to a modern cavopulmonary connection, combined with a modified maze procedure in the right atrium. It is clear from early surgical experience81 that hemodynamic conversion by itself is insufficient to eliminate IART. A formal right-sided maze must be incorporated into the operation, using a lesion set that consists of linear ablation at 3 regions: (1) the upper rim of the atrial septal defect toward the superior vena cava and right atrial appendage, (2) the posterior-inferior rim of the atrial septal defect toward the crista terminalis and edge of the atriotomy incision, and (3) the coronary sinus and right AV valve (when such a valve is present) toward the inferior vena cava.82 Placement of an epicardial atrial pacemaker typically is included for sinus node dysfunction, which will likely be present postoperatively if it was not already an issue preoperatively.83 For occasional Fontan patients who have atrial fibrillation in addition to IART, the maze can be extended to the left atrium with a variation of the Cox procedure.84
Fontan conversion with an atrial maze has a very good record for eliminating atrial tachycardia. Initial estimates of recurrence85 were on the order of 12% but are perhaps even lower now that the proper ablation lesion set has been better defined.86 Still, it is a major operation with a combined risk of mortality or need for postoperative heart transplant that exceeds 5%, and these risks must be balanced carefully against the potential electrophysiological benefit.84
Pulmonary Valve Replacement in Tetralogy of Fallot
Successful relief of right ventricular outflow obstruction during tetralogy repair often requires sacrifice of pulmonary valve competence. Regurgitation can be tolerated for many years, but the resultant volume load can eventually cause right ventricular dysfunction and increase the risk of VT. Many patients with advanced degrees of regurgitation are now undergoing pulmonary valve replacement in an effort to address this issue. Among those known to have reentrant VT preoperatively, simply replacing the valve does not appear to eliminate the underlying VT substrate, but if formal mapping and surgical cryoablation of circuit tissue are performed, VT can be eliminated in most cases.36
The hemodynamic benefit of valve replacement in tetralogy patients with right-heart dilation seems well established,87–89 but the exact risk of VT recurrence after surgical ablation is less clear. Estimates of VT recurrence range between 0% and 30% in published series.36,90,91 Whether the intervention can ever dismiss consideration of an implantable defibrillator in high-risk cases remains uncertain, but like catheter ablation, it could serve the role of reducing defibrillator shocks in patients who already have a device in place. Studies are now underway to test whether earlier valve replacement in tetralogy (ie, before the appearance of significant right ventricular failure) will prevent development of late VT.92,93
|
Pacemaker and Implantable Defibrillator Therapy in CHD Patients |
|---|
|
TopIntroductionMechanism and Incidence of...Catheter Ablation in CHDSurgery for Arrhythmias in...Pacemaker and Implantable...ConclusionsReferences |
|---|
Indications for pacemaker and defibrillator implantation in CHD patients have been reviewed and updated as part of the guidelines published by the American College of Cardiology/American Heart Association/North American Society for Pacing and Electrophysiology task force.94 The most important considerations surrounding device therapy in this population relate to lead placement, which must take into account distorted anatomy and the risk for thromboembolic complications.
Lead Placement
Transvenous access for pacemaker or defibrillator leads in CHD often is difficult. The challenge is well demonstrated by patients after the Fontan operation, who usually lack a standard venous connection to their single ventricle and may be at risk for large thrombus formation on atrial leads unless chronically anticoagulated. Although transvenous atrial lead placement is possible in select cases, an epicardial approach typically is used for ventricular leads. Transvenous ventricular pacing can sometimes be accomplished with a lead advanced into a ventricular branch off the coronary sinus in patients with the old variety of atriopulmonary Fontan anastomosis, but this option is not available for those with modern cavopulmonary connections.95,96
The venous route to the atrium and ventricle in Mustard or Senning patients is likewise challenging. Transvenous leads need to be advanced through the atrial baffle before fixation in the modified right atrium and the anatomic left ventricle, and it is not uncommon to encounter tight obstruction along the upper limb of the baffle that requires dilation and stent placement before leads can be passed. Baffle leaks with right-to-left shunting also might be present that necessitate closure with an occlusion device or surgery before a lead is inserted into the circulation.97 Finally, distorted atrial anatomy must be understood clearly to allow atrial lead fixation in the few areas of atrial muscle that are away from patches, scars, and the left phrenic nerve (Figure 7A through 7D).
|
The incidence of thromboembolic complications is significant when transvenous leads are used in CHD patients with residual intracardiac shunting from patch leaks or open septal defects.98 If such defects cannot be closed in advance of lead implantation, an epicardial approach may have to be considered.
The need for epicardial pacemaker or defibrillator leads can sometimes be anticipated during a primary cardiac repair, in which case the cardiac surface is easily visualized in the scar-free mediastinum. Modern bipolar epicardial leads with steroid-eluting features function nearly as well as endocardial leads under these circumstances.99 Unfortunately, many epicardial implantations have to be done in older CHD patients who have undergone prior operations, which presents the surgeon with a scarred mediastinum that must be dissected carefully and deliberately to find suitable lead attachment points. It is much more of a chore to identify sites with adequate sensing function and capture thresholds when dense adhesions cover the heart, and long-term lead performance can suffer as a result.
Resynchronization Pacing in CHD
The optimistic results reported with biventricular resynchronization pacing in patients with normal cardiac anatomy and dilated myopathy have inspired parallel trials in the CHD population. The experience to date has been encouraging. In a multicenter review of 73 patients with CHD undergoing resynchronization therapy,100 a mean increase in systemic ventricular ejection fraction of 12% was observed, along with a mean decrease in QRS duration of 39 milliseconds. The degree of improvement was similar with endocardial and epicardial leads. A good response did not seem to hinge on whether a left or right ventricle was the systemic pumping chamber, although patients with a single ventricle were unlikely to improve in this series despite shortening of the QRS width.
The concept of resynchronization also has also extended to CHD patients with right bundle-branch block and a failing right ventricle, as can occur in the older population with repaired tetralogy of Fallot. Selective placement of a ventricular pacing lead to a site that offsets right ventricular conduction delay seems to enhance contractile performance of the right ventricle,101,102 although long-term experience with this technique is limited.
Atrial Antitachycardia Pacing in CHD
The high incidence of tachy-brady syndrome in CHD has prompted trials of pacemakers equipped with automatic features to detect IART and attempt interruption with burst atrial pacing.103 In patients with a single circuit of relatively slow IART, this technology tends to be quite successful. However, difficulty may arise in those with multiple IART circuits because burst pacing can shift tachycardia to different cycle lengths or cause degeneration to atrial fibrillation, sometimes with a faster ventricular response and worsened symptoms.104 Overall, automatic antitachycardia pacing can be successful therapy for IART in 50% of patients.105,106
Implantable Defibrillators in CHD
Implantable defibrillators are being used with increasing frequency in the CHD population.35,107 The most common CHD diagnosis among defibrillator recipients is tetralogy of Fallot, followed by D-TGA and aortic stenosis. Transvenous dual-chamber systems are possible in most cases, except for patients with significant intracardiac shunts, a single ventricle after the Fontan operation, or very small body size. Numerous configurations of coils and patches have been described for shock delivery (Figure 8) when epicardial implantation is the only option.108,109
|
Defibrillation thresholds measured in CHD patients with either transvenous or epicardial systems are similar to those obtained in patients with conventional cardiac anatomy. Long-term data on defibrillator performance suggest appropriate shock therapy in 30% of CHD patients over 5 years of follow-up,35 with inappropriate shocks in 25% (mostly for sinus tachycardia) and lead failure (requiring revision) in 21%. The somewhat-high lead failure rate may reflect the vigorous lifestyle enjoyed by most adolescents and young adults with CHD compared with the older population with ischemic disease.
|
Conclusions |
|---|
|
TopIntroductionMechanism and Incidence of...Catheter Ablation in CHDSurgery for Arrhythmias in...Pacemaker and Implantable...ConclusionsReferences |
|---|
Older CHD patients who underwent repair or palliation with antiquated surgical techniques suffer from a wide variety of rhythm disturbances. Interventional electrophysiological techniques play a major role in their management. Although procedures often are complicated by atypical anatomy and the presence of intracardiac shunting, a high level of success can be achieved with careful attention to surgical history and modern imaging technology. Modifications in surgical technique have done much to reduce rhythm complications for the current generation of CHD patients.
|
Acknowledgments |
|---|
Disclosures
None.
|
Footnotes |
|---|
Guest Editor for this article was Michael E. Cain, MD.
|
References |
|---|
|
TopIntroductionMechanism and Incidence of...Catheter Ablation in CHDSurgery for Arrhythmias in...Pacemaker and Implantable...ConclusionsReferences |
|---|
1. Holt LE. Congenital anomalies of the heart. In: Holt LE, McIntosh R, eds. Holt’s Diseases of Infancy and Childhood. 10th ed. New York, NY: Appleton Century; 1933: 510.
2. Hoffman JIE. Incidence, mortality, and natural history. In: Anderson RH, Baker EJ, McCarthy FJ, Rigby ML, Shinebourne EA, Tynan M, eds. Paediatric Cardiology. 2nd ed. London, UK: Churchill Livingston; 2002: 111–140.
3. Nakagawa H, Shah N, Matsudaira K, Overholt E, Chandrasekaran K, Beckman KJ, Spector P, Calame JD, Rao A, Hasdemir C, Otomo K, Wang Z, Lazzara R, Jackman WM. Characterization of reentrant circuit in macroreentrant right atrial tachycardia after surgical repair of congenital heart disease: isolated channels between scars allow "focal" ablation. Circulation. 2001; 103: 699–709.
4. Kalman JK, Van Hare GF, Olgin JE, Saxon LA, Stark SI, Lesh MD. Ablation of incisional reentrant atrial tachycardia complicating surgery for congenital heart disease. Circulation. 1996; 93: 502–512.
5. Triedman JK, Jenkins KJ, Colan SD, Saul JP, Walsh EP. Intra-atrial reentrant tachycardia after palliation of congenital heart disease: characterization of multiple macroreentrant circuits using fluoroscopically based three-dimensional endocardial mapping. J Cardiovasc Electrophysiol. 1997; 8: 259–270.[Medline] [Order article via Infotrieve]
6. Garson A, Bink-Boelkens MTE, Hesslein PS, Hordof AJ, Keane JF, Neches WH, Porter CJ. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol. 1985; 6: 871–878.[Abstract]
7. Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol. 1994; 24: 1365–1370.[Abstract]
8. Roos-Hesselink J, Perlroth MG, McGhie J, Spitaels S. Atrial arrhythmias in adults after repair of tetralogy of Fallot: correlations with clinical, exercise, and echocardiographic findings. Circulation. 1995; 91: 2214–2219.
9. Fishberger SB, Wernovsky G, Gentles TL, Gauvreau K, Burnett J, Mayer JE, Walsh EP. Factors that influence the development of atrial flutter after the Fontan operation. J Thorac Cadiovas Surg. 1997; 113: 80–86.[CrossRef]
10. Cecchin F, Johnsrude CL, Perry JC, Friedman RA. Effect of age and surgical technique on symptomatic arrhythmias after the Fontan procedure. Am J Cardiol. 1995; 76: 386–391.[CrossRef][Medline] [Order article via Infotrieve]
11. Flinn CJ, Wolff GS, Dick M, Campbell RM, Borkat G, Casta A, Hordof A, Hougen TJ, Kavey RE, Kugler J. Cardiac rhythm after the Mustard operation for complete transposition of the great arteries. N Engl J Med. 1984; 3310: 1635–1638.
12. Triedman JK. Atrial reentrant tachycardias. In: Walsh EP, Saul JP, Triedman JK, eds. Cardiac Arrhythmias in Children and Young Adults With Congenital Heart Disease. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001: 137–160.
13. Kirsh JA, Walsh EP, Triedman JK. Prevalence of and risk factors for atrial fibrillation and intraatrial reentrant tachycardia among patients with congenital heart disease. Am J Cardiol. 2002; 90: 338–340.[CrossRef][Medline] [Order article via Infotrieve]
14. Saul JP, Walsh EP, Triedman JK. Mechanisms and therapy of complex arrhythmias in pediatric patients. J Cardiovasc Electrophysiol. 1996; 6: 1129–1148.
15. Attenhofer Jost CH, Connolly HM, Edwards WD, Hayes D, Warnes CA, Danielson GK. Ebstein’s anomaly: review of a multifaceted congenital cardiac condition. Swiss Med Wkly. 2005; 135: 269–281.[Medline] [Order article via Infotrieve]
16. Oh JK, Holmes DR Jr, Hayes DL, Porter CB, Danielson GK. Cardiac arrhythmias in patients with surgical repair of Ebstein’s anomaly. J Am Coll Cardiol. 1985; 6: 1351–1357.[Abstract]
17. Smith WM, Gallagher JJ, Kerr CR, Sealy WC, Kasell JH, Benson DW, Reiter MJ, Sterba R, Grant AO. The electrophysiologic basis and management of symptomatic recurrent tachycardia in patients with Ebstein’s anomaly of the tricuspid valve. Am J Cardiol. 1982; 49: 1223–1234.[CrossRef][Medline] [Order article via Infotrieve]
18. Harrison DA, Harris L, Siu SC, MacLoghlin CJ, Connelly MS, Webb GD, Downer E, McLaughlin PR, Williams WG. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. 1997; 30: 1368–1373.[Abstract]
19. Horowitz LN, Vetter VL, Harken AH, Josephson ME. Electrophysiologic characteristics of sustained ventricular tachycardia occurring after repair of tetralogy of Fallot. Am J Cardiol. 1980; 46: 446–452.[CrossRef][Medline] [Order article via Infotrieve]
20. Downar E, Harris L, Kimber S, Mickleborough L, Williams W, Sevaptsidis E, Masse S, Chen TC, Chan A, Genga A. Ventricular tachycardia after surgical repair of tetralogy of Fallot: results of intraoperative mapping studies. J Am Coll Cardiol. 1992; 20: 648–655.[Abstract]
21. Wolfe RR, Driscoll DJ, Gersony WM, Hayes CJ, Keane JF, Kidd L, O’Fallon WM, Pieroni DR, Weidman WH. Arrhythmias in patients with valvar aortic stenosis, valvar pulmonary stenosis, and ventricular septal defect: results of 24-hour ECG monitoring. Circulation. 1993; 87 (suppl): I-89–I-101.[Medline] [Order article via Infotrieve]
22. Keane JF, Driscoll DJ, Gersony WM, Hayes CJ, Kidd L, O’Fallon WM, Pieroni DR, Wolfe RR, Weidman WH. Second natural history study of congenital heart defects: results of treatment of patients with aortic valvar stenosis. Circulation. 1993; 87 (suppl): I-16–I-27.[Medline] [Order article via Infotrieve]
23. Gatzoulis MA, Walters J, McLaughlin PR, Merchant N, Webb GD, Liu P. Late arrhythmia in adults with the mustard procedure for transposition of great arteries: a surrogate marker for right ventricular dysfunction? Heart. 2000; 84: 409–415.
24. Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoon MD, Ilstrup DM, McGoon DC, Kirklin JW, Danielson GK. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. 1993; 329: 593–599.
25. Deanfield JE, McKenna WJ, Presbitero P, England D, Graham GR, Hallidie-Smith K. Ventricular arrhythmia in unrepaired and repaired tetralogy of Fallot. Relation to age, timing of repair, and haemodynamic status. Br Heart J. 1984; 52: 77–81.
26. Nollert G, Fischlein T, Bouterwek S, Bohmer C, Klinner W, Reichart B. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol. 1997; 30: 1374–1383.[Abstract]
27. Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998; 32: 245–251.
28. Norgaard MA, Lauridsen P, Helvind M, Pettersson G. Twenty-to-thirty-seven-year follow-up after repair for tetralogy of Fallot. Eur J Cardiothorac Surg. 1999; 16: 125–130.
29. Garson A Jr, Nihill MR, McNamara DG, Cooley DA. Status of the adult and adolescent after repair of tetralogy of Fallot. Circulation. 1979; 59: 1232–1240.
30. Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, Rosenthal M, Nakazawa M, Moller JH, Gillette PC, Webb GD, Redington AN. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000; 356: 975–981.[CrossRef][Medline] [Order article via Infotrieve]
31. Kavey RE, Thomas FD, Byrum CJ, Blackman MS, Sondheimer HM, Bove EL. Ventricular arrhythmias and biventricular dysfunction after repair of tetralogy of Fallot. J Am Coll Cardiol. 1984; 4: 126–131.[Abstract]
32. Burns RJ, Liu PP, Druck MN, Seawright SJ, Williams WG, McLaughlin PR. Analysis of adults with and without complex ventricular arrhythmias after repair of tetralogy of Fallot. J Am Coll Cardiol. 1984; 4: 226–233.[Abstract]
33. Cullen S, Celermajer DS, Franklin RC, Hallidie-Smith KA, Deanfield JE. Prognostic significance of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year prospective study. J Am Coll Cardiol. 1994; 23: 1151–1155.[Abstract]
34. Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, Marçon F, Walsh EP. Prognostic significance of electrophysiologic testing post tetralogy of Fallot repair: a multicenter study. Circulation. 2004; 109: 1994–2000.
35. Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI. Implications of implantable defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol. 2004; 15: 72–76.[Medline] [Order article via Infotrieve]
36. Therrien J, Siu SC, Harris L, Dore A, Niwa K, Janousek J, Williams WG, Webb G, Gatzoulis MA. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation. 2001; 103: 2489–2494.
37. Manning PB, Mayer JE, Wernovsky G, Fishberger SB, Walsh EP. Staged operation to Fontan increases the incidence of sinoatrial node dysfunction. J Thorac Cardiovasc Surg. 1996; 111: 833–840.
38. Anderson RH, Ho SY. The disposition of the conduction tissues in congenitally malformed hearts with reference to their embryological development. J Perinat Med. 1991; 19: 201–206.[Medline] [Order article via Infotrieve]
39. Lev M, Licata RH, May RC. The conduction system in mixed levocardia with ventricular inversion (corrected transposition). Circulation. 1963; 28: 232–237.
40. Anderson RH, Becker AE, Arnold R, Wilkinson JL. The conducting tissues in congenitally corrected transposition. Circulation. 1974; 50: 911–923.
41. Thiene G, Wenick ACG, Frescura C, Wilkinson JL, Gallucci V, Ho SY, Mazzucco A, Anderson RH. Surgical anatomy and pathology of the conduction tissues in atrioventricular defects. J Thorac Cardiovasc Surg. 1981; 82: 928–937.[Medline] [Order article via Infotrieve]
42. Huhta JC, Maloney JD, Ritter DG, Ilstrup DM, Feldt RH. Complete atrioventricular block in patients with atrioventricular discordance. Circulation. 1983; 67: 1374–1377.
43. Connelly MS, Liu PP, Williams WG, Webb GD, Robertson P, McLaughlin PR. Congenitally corrected transposition of the great arteries in the adult: functional status and complications. J Am Coll Cardiol. 1996; 27: 1238–1243.[Abstract]
44. Dick M, Norwood WI, Chipman C, Castaneda AR. Intraoperative recording of specialized atrioventricular conduction tissue electrograms in 47 patients. Circulation. 1979; 59: 150–160.
45. Weindling SN, Gamble WJ, Mayer JE, Walsh EP. Duration of complete atrioventricular block after congenital heart disease surgery. Am J Cardiol. 1998; 82: 525–527.[CrossRef][Medline] [Order article via Infotrieve]
46. Levine J, Walsh EP, Saul JP. Catheter ablation of accessory pathways in patients with congenital heart disease including heterotaxy syndrome. Am J Cardiol. 1993; 72: 689–694.[CrossRef][Medline] [Order article via Infotrieve]
47. Triedman JK, Alexander MA, Love BA, Collins KK, Berul CI, Bevilacqua LM, Walsh EP. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial tachycardia in patients with congenital heart disease. J Am Coll Cardiol. 2002; 39: 1827–1835.
48. Triedman JK, Delucca JM, Alexander ME, Berul CI, Cecchin F, Walsh EP. Prospective trial of electroanatomically guided, irrigated catheter ablation of atrial tachycardia in patients with congenital heart disease. Heart Rhythm. 2005; 2: 700–705.[CrossRef][Medline] [Order article via Infotrieve]
49. Collins KK, Love BA, Walsh EP, Saul JP, Epstein MR, Triedman JK. Location of acutely successful radiofrequency catheter ablation of intraatrial reentrant tachycardia in patients with congenital heart disease. Am J Cardiol. 2000; 86: 969–974.[CrossRef][Medline] [Order article via Infotrieve]
50. Van Hare GF. Electrical-anatomic correlations between typical atrial flutter and intra-atrial re-entry following atrial surgery. J Electrocardiol. 1998; 30 (suppl): 77–84.[CrossRef][Medline] [Order article via Infotrieve]
51. Kanter RJ, Papagiannis J, Carboni MP, Ungerleider RM, Sanders WE, Wharton JM. Radiofrequency catheter ablation of supraventricular tachycardia substrates after Mustard and Senning operations for d-transposition of the great arteries. J Am Coll Cardiol. 2000; 35: 428–441.
52. Van Hare GF, Lesh MD, Ross BA, Perry JC, Dorostkar PC. Mapping and radiofrequency ablation of intraatrial reentrant tachycardia after the Senning or Mustard procedure for transposition of the great arteries. Am J Cardiol. 1996; 77: 985–991.[CrossRef][Medline] [Order article via Infotrieve]
53. Perry JC, Boramanand NK, Ing FF. "Transseptal" technique through atrial baffles for 3-dimensional mapping and ablation of atrial tachycardia in patients with d-transposition of the great arteries. J Interv Card Electrophysiol. 2003; 9: 365–369.[CrossRef][Medline] [Order article via Infotrieve]
54. Triedman JK, Alexander ME, Berul CI, Bevilacqua LM, Walsh EP. Electroanatomic mapping of entrained and exit zones in patients with repaired congenital heart disease and intra-atrial reentrant tachycardia. Circulation. 2001; 103: 2060–2065.
55. Mandapati R, Walsh EP, Triedman JK. Pericaval and periannular intra-atrial reentrant tachycardias in patients with congenital heart disease. J Cardiovasc Electrophysiol. 2003; 14: 119–112.[Medline] [Order article via Infotrieve]
56. Delacretaz E, Ganz LI, Friedman PL, Walsh EP, Triedman JK, Sloss LJ, Landzberg MJ, Stevenson WG. Multiple atrial macroreentry circuits in adults with repaired congenital heart disease: entrainment mapping combined with three-dimensional electroanatomic mapping. J Am Coll Cardiol. 2001; 37: 1665–1676.
57. Triedman JK, Bergau DM, Saul JP, Epstein MR, Walsh EP. Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol. 1997; 30: 1032–1038.[Abstract]
58. Reich JD, Auld D, Hulse E, Sullivan K, Campbell R. The Pediatric Radiofrequency Ablation Registry’s experience with Ebstein’s anomaly: Pediatric Electrophysiology Society. J Cardiovasc Electrophysiol. 1998; 9: 1370–1377.[Medline] [Order article via Infotrieve]
59. Chetaille P, Walsh EP, Triedman JK. Outcomes of radiofrequency catheter ablation of atrioventricular reciprocating tachycardia in patients with congenital heart disease. Heart Rhythm. 2004; 1: 168–173.[CrossRef][Medline] [Order article via Infotrieve]
60. Shah MJ, Jones TK, Cecchin F. Improved localization of right-sided accessory pathways with microcatheter-assisted right coronary artery mapping in children. J Cardiovasc Electrophysiol. 2004; 15: 1238–1243.[CrossRef][Medline] [Order article via Infotrieve]
61. Bertram H, Bokenkamp R, Peuster M, Hausdorf G, Paul T. Coronary artery stenosis after radiofrequency catheter ablation of accessory atrioventricular pathways in children with Ebstein’s malformation. Circulation. 2001; 103: 538–543.
62. Van Hare GF, Lesh MD, Stanger P. Radiofrequency catheter ablation of supraventricular arrhythmias in patients with congenital heart disease: results and technical considerations. J Am Coll Cardiol. 1993; 22: 883–890.[Abstract]
63. Bar-Cohen Y, Cecchin F, Alexander ME, Berul CI, Triedman JK, Walsh EP. Cryoablation for accessory pathways located near normal conduction tissues or within the coronary venous system in children and young adults. Heart Rhythm. 2006; 3: 253–258.[CrossRef][Medline] [Order article via Infotrieve]
64. Burton ME, Leon AR. Radiofrequency catheter ablation of right ventricular outflow tract tachycardia late after complete repair of tetralogy of Fallot using the pace mapping technique. Pacing Clin Electrophysiol. 1993; 16: 2319–2325.[CrossRef][Medline] [Order article via Infotrieve]
65. Biblo LA, Carlson MD. Transcatheter radiofrequency ablation of ventricular tachycardia following surgical correction of tetralogy of Fallot. Pacing Clin Electrophysiol. 1994; 17: 1556–1560.[CrossRef][Medline] [Order article via Infotrieve]
66. Goldner BG, Cooper R, Blau W, Cohen TJ. Radiofrequency catheter ablation as a primary therapy for treatment of ventricular tachycardia in a patient after repair of tetralogy of Fallot. Pacing Clin Electrophysiol. 1994; 17: 1441–1446.[CrossRef][Medline] [Order article via Infotrieve]
67. Chinushi M, Aizawa Y, Kitazawa H, Kusano Y, Washizuka T, Shibata A. Successful radiofrequency catheter ablation for macroreentrant ventricular tachycardias in a patient with tetralogy of Fallot after corrective surgery. Pacing Clin Electrophysiol. 1995; 18: 1713–1716.[Medline] [Order article via Infotrieve]
68. Horton RP, Canby RC, Kessler DJ, Joglar JA, Hume A, Jessen ME, Scott WP, Page RL. Ablation of ventricular tachycardia associated with tetralogy of Fallot: demonstration of bidirectional block. J Cardiovasc Electrophysiol. 1997; 8: 432–435.[Medline] [Order article via Infotrieve]
69. Stevenson WG, Delacretaz E, Friedman PL, Ellison KE. Identification and ablation of macroreentrant ventricular tachycardia with the CARTO electroanatomical mapping system. Pacing Clin Electrophysiol. 1998; 21: 1448–56.[CrossRef][Medline] [Order article via Infotrieve]
70. Papagiannis J, Kanter RJ, Wharton JM. Radiofrequency catheter ablation of multiple haemodynamically unstable ventricular tachycardias in a patient with surgically repaired tetralogy of Fallot. Cardiol Young. 1998; 8: 379–82.[Medline] [Order article via Infotrieve]
71. Saul JP, Alexander ME. Preventing sudden death after repair of tetralogy of Fallot: complex therapy for complex patients. J Cardiovasc Electrophysiol. 1999; 10: 1271–1287.[Medline] [Order article via Infotrieve]
72. Rostock T, Willems S, Ventura R, Weiss C, Risius T, Meinertz T. Radiofrequency catheter ablation of a macroreentrant ventricular tachycardia late after surgical repair of tetralogy of Fallot using the electroanatomic mapping (CARTO). Pacing Clin Electrophysiol. 2004; 27: 801–804.[CrossRef][Medline] [Order article via Infotrieve]
73. Frangini P, Vergara I, Fajuri A, Gonzalez R, Baeza M. Radiofrequency ablation of ventricular tachycardia in a patient after surgery for tetralogy of Fallot: case report. Rev Med Chil. 2005; 133: 675–680.[Medline] [Order article via Infotrieve]
74. Gonska BD, Cao K, Raab J, Eigster G, Kreuzer H. Radiofrequency catheter ablation of right ventricular tachycardia late after repair of congenital heart defects. Circulation. 1996; 94: 1902–1908.
75. Morwood JG, Triedman JK, Berul CI, Khairy P, Alexander ME, Cecchin F, Walsh EP. Radiofrequency catheter ablation of ventricular tachycardia in children, and in young adults with congenital heart disease. Heart Rhythm. 2004; 1: 301–308.[CrossRef][Medline] [Order article via Infotrieve]
76. Rhodes LA, Wernovsky G, Keane JF, Mayer JE, Shuren A, Dindy C, Colan SD, Walsh EP. Arrhythmias and intracardiac conduction after the arterial switch operation. J Thorac Cardiovas Surg. 1995; 109: 303–310.
77. Stamm C, Friehs I, Mayer JE Jr, Zurakowski D, Triedman JK, Moran AM, Walsh EP, Lock JE, Jonas RA, Del Nido PJ. Long-term results of the lateral tunnel Fontan operation. J Thorac Cardiovasc Surg. 2001; 121: 28–41.[CrossRef][Medline] [Order article via Infotrieve]
78. Giannico S, Hammad F, Amodeo A, Michielon G, Drago F, Turchetta A, Di Donato R, Sanders SP. Clinical outcome of 193 extracardiac Fontan patients: the first 15 years. J Am Coll Cardiol. 2006; 47: 2065–2073.
79. Walsh EP, Rockenmacher S, Keane JF, Hougen TJ, Lock JE, Castaneda AR. Late results in patients with tetralogy of Fallot repaired during infancy. Circulation. 1988; 77: 1062–1067.
80. Hamada H, Terai M, Jibiki T, Nakamura T, Gatzoulis MA, Niwa K. Influence of early repair of tetralogy of Fallot without an outflow patch on late arrhythmias and sudden death: a 27-year follow-up study following a uniform surgical approach. Cardiol Young. 2002; 12: 345–351.[Medline] [Order article via Infotrieve]
81. Kreutzer J, Keane JF, Lock JE, Walsh EP, Jonas RA, Castaneda AR, Mayer JE. Conversion of modified Fontan procedure to lateral atrial tunnel cavopulmonary anastomosis. J Thorac Cardiovasc Surg. 1996; 111: 1169–1176.
82. Deal BJ, Mavroudis C, Backer CL, Buck SH, Johnsrude C. Comparison of anatomic isthmus block with the modified right atrial maze procedure for late atrial tachycardia in Fontan patients. Circulation. 2002; 106: 575–579.
83. Weinstein S, Chan D. Extracardiac Fontan conversion, cryoablation, and pacemaker placement for patients with a failed Fontan. Semin Thorac Cardiovasc Surg. 2005; 17: 170–178.[CrossRef][Medline] [Order article via Infotrieve]
84. Mavroudis C, Deal BJ, Backer CL. Surgery for arrhythmias in children. Int J Cardiol. 2004; 97 (suppl): 39–51.[CrossRef][Medline] [Order article via Infotrieve]
85. Deal BJ, Mavroudis C, Backer CL, Johnsrude CL, Rocchini AP. Impact of arrhythmia circuit cryoablation during Fontan conversion for refractory atrial tachycardia. Am J Cardiol. 1999; 83: 563–568.[CrossRef][Medline] [Order article via Infotrieve]
86. Mavroudis C, Backer CL, Deal BJ, Johnsrude C, Strasburger J. Total cavopulmonary conversion and maze procedure for patients with failure of the Fontan operation. J Thorac Cardiovasc Surg. 2001; 122: 863–871.
87. van Straten A, Vliegen HW, Lamb HJ, Roes SD, van der Wall EE, Hazekamp MG, de Roos A. Time course of diastolic and systolic function improvement after pulmonary valve replacement in adult patients with tetralogy of Fallot. J Am Coll Cardiol. 2005; 46: 1559–1564.
88. Vliegen HW, van Straten A, de Roos A, Roest AA, Schoof PH, Zwinderman AH, Ottenkamp J, van der Wall EE, Hazekamp MG. Magnetic resonance imaging to assess the hemodynamic effects of pulmonary valve replacement in adults late after repair of tetralogy of Fallot. Circulation. 2002; 106: 1703–1707.
89. Eyskens B, Reybrouck T, Bogaert J, Dymarkowsky S, Daenen W, Dumoulin M, Gewillig M. Homograft insertion for pulmonary regurgitation after repair of tetralogy of Fallot improves cardiorespiratory exercise performance. Am J Cardiol. 2000; 85: 221–225.[CrossRef][Medline] [Order article via Infotrieve]
90. Karamlou T, Silber I, Lao R, McCrindle BW, Harris L, Downar E, Webb GD, Colman JM, Van Arsdell GS, Williams WG. Outcomes after late reoperation in patients with repaired tetralogy of Fallot: the impact of arrhythmia and arrhythmia surgery. Ann Thorac Surg. 2006; 81: 1786–1793.
91. Harrison DA, Harris L, Siu SC, MacLoghlin CJ, Connelly MS, Webb GD, Downar E, McLaughlin PR, Williams WG. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. 1997; 30: 1368–1373.[Abstract]
92. Therrien J, Siu SC, McLaughlin PR, Liu PP, Williams WG, Webb GD. Pulmonary valve replacement in adults late after repair of tetralogy of Fallot: are we operating too late? J Am Coll Cardiol. 2000; 36: 1670–1675.
93. d’Udekem Y, Rubay J, Ovaert C. Failure of right ventricular recovery of Fallot patients after pulmonary valve replacement: delay of reoperation or surgical technique? J Am Coll Cardiol. 2001; 37: 2008–2009.
94. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol. 2002; 40: 1703–1719.
95. Shah MJ, Nehgme R, Carboni M, Murphy JD. Endocardial atrial pacing lead implantation and midterm follow-up in young patients with sinus node dysfunction after the Fontan procedure. Pacing Clin Electrophysiol. 2004; 27: 949–954.[CrossRef][Medline] [Order article via Infotrieve]
96. Hansky B, Blanz U, Peuster M, Gueldner H, Sandica E, Crespo-Martinez E, Mathies W, Meyer H, Koerfer R. Endocardial pacing after Fontan-type procedures. Pacing Clin Electrophysiol. 2005; 28: 140–148.[CrossRef][Medline] [Order article via Infotrieve]
97. Knauth AL, Lock JE, Perry SB, McElhinney DB, Gauvreau K, Landzberg MJ, Rome JJ, Hellenbrand WE, Ruiz CE, Jenkins KJ. Transcatheter device closure of congenital and postoperative residual ventricular septal defects. Circulation. 2004; 110: 501–507.
98. Khairy P, Landzberg MJ, Gatzoulis MA, Mercier LA, Fernades SM, Côté JM, Lavoie JP, Fournier A, Guerra PG, Frogoudaki A, Walsh EP, Dore A. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation. 2006; 113: 2391–2397.
99. Cohen MI, Bush DM, Vetter VL, Tanel RE, Wieand TS, Gaynor JW, Rhodes LA. Permanent epicardial pacing in pediatric patients: seventeen years of experience and 1200 outpatient visits. Circulation. 2001; 103: 2585–2590.
100. Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, Shannon KM, Temple J, Rosenthal E, Zimmerman FJ, Davis A, Karpawich PP, Al Ahmad A, Vetter VL, Kertesz NJ, Shah M, Snyder C, Stephenson E, Emmel M, Sanatani S, Kanter R, Batra A, Collins KK. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol. 2005; 46: 2277–2283.
101. Stephenson EA, Cecchin F, Alexander ME, Triedman JK, Walsh EP, Berul CI. Relation of right ventricular pacing in tetralogy of Fallot to electrical resynchronization. Am J Cardiol. 2004; 93: 1449–1452.[CrossRef][Medline] [Order article via Infotrieve]
102. Dubin AM, Feinstein JA, Reddy VM, Hanley FL, Van Hare GF, Rosenthal DN. Electrical resynchronization: a novel therapy for the failing right ventricle. Circulation. 2003; 107: 2287–2289.
103. Gillette PC, Zeigler VL, Case CL, Harold M, Buckles DS. Atrial antitachycardia pacing in children and young adults. Am Heart J. 1991; 122: 844–849.[CrossRef][Medline] [Order article via Infotrieve]
104. Rhodes LA, Walsh EP, Gamble WJ, Triedman JK, Saul JP. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. Pacing Clin Electrophysiol. 1995; 18: 1005–1016.[CrossRef][Medline] [Order article via Infotrieve]
105. Balaji S, Johnson TB, Sade RM, Case CL, Gillette PC. Management of atrial flutter after the Fontan procedure. J Am Coll Cardiol. 1994; 23: 1209–1215.[Abstract]
106. Stevenson EA, Casavant D, Tuzi J, Alexander MA, Law I, Serwer G, Strieper M, Walsh EP, Berul CI. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol. 2003; 92: 871–876.[CrossRef][Medline] [Order article via Infotrieve]
107. Dore A, Santagata P, Dubuc M, Mercier LA. Implantable cardioverter defibrillators in adults with congenital heart disease: a single center experience. Pacing Clin Electrophysiol. 2004; 1: 47–51.
108. Cannon BC, Friedman RA, Fenrich AL, Fraser CD, McKenzie ED, Kertesz NJ. Innovative techniques for placement of implantable cardioverter-defibrillator leads in patients with limited venous access to the heart. Pacing Clin Electrophysiol. 2006; 29: 181–187.[CrossRef][Medline] [Order article via Infotrieve]
109. Stephenson EA, Batra AS, Knilans TK, Gow RM, Gradaus R, Balaji S, Dubin AM, Rhee EK, Ro PS, Thogersen AM, Cecchin F, Triedman JK, Walsh EP, Berul CI. A multicenter experience with novel implantable cardioverter defibrillator configurations in the pediatric and congenital heart disease population. J Cardiovasc Electrophysiol. 2006; 17: 41–46.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M M Winter, B J Bouma, M Groenink, T C Konings, J G P Tijssen, D J van Veldhuisen, and B J M Mulder Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure Heart, June 15, 2009; 95(12): 960 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Aliot, W. G. Stevenson, J. M. Almendral-Garrote, F. Bogun, C. H. Calkins, E. Delacretaz, P. D. Bella, G. Hindricks, P. Jais, M. E. Josephson, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA) Europace, June 1, 2009; 11(6): 771 - 817. [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Mascio, C. L. Johnsrude, E. S. Kim, and E. H. Austin III Bidirectional Glenn with Existing Transvenous Cardioverter-Defibrillator Leads Ann. Thorac. Surg., April 1, 2009; 87(4): e34 - e36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.#x.;n. Farré, H. J.J. Wellens, J.#x. M. Rubio, and J. Benezet CHAPTER 28 Supraventricular Tachycardias ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Medi and J. M. Kalman Prediction of the atrial flutter circuit location from the surface electrocardiogram Europace, July 1, 2008; 10(7): 786 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Bakker, B. J. Boukens, M. T.M. Mommersteeg, J. F. Brons, V. Wakker, A. F.M. Moorman, and V. M. Christoffels Transcription Factor Tbx3 Is Required for the Specification of the Atrioventricular Conduction System Circ. Res., June 6, 2008; 102(11): 1340 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bedard, D. F. Shore, and M. A. Gatzoulis Adult congenital heart disease: a 2008 overview Br. Med. Bull., March 1, 2008; 85(1): 151 - 180. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||